Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.

P Jiménez-Fonseca, J M Gómez Saez, J Santamaria Sandi, J Capdevila, E Navarro Gonzalez, C Zafon Llopis, T Ramón Y Cajal Asensio, G Riesco-Eizaguirre, E Grande, J C Galofré

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017;19(1):12-20

PMID: 27048161

Full Text on Springer View on PubMed

Abstract

Anaplastic thyroid cancer (ATC) is the most aggressive solid tumor and almost uniformly lethal in humans. The Boards of the Thyroid Cancer Group of the Spanish Society of Endocrinology and Nutrition and the Grupo Español de Enfermedades Huérfanas e Infrecuentes of the Spanish Society of Oncology requested that an independent task force draft a more comprehensive consensus statement regarding ATC. All relevant literature was reviewed, including serial PubMed searches together with additional articles. This is the first, comprehensive Spanish consensus statement for ATC and includes the characteristics, diagnosis, initial evaluation, treatment goals, recommendations and modalities for locoregional and advanced disease, palliative care options, surveillance, and long-term monitoring. Newer systemic therapies are being investigated, but more effective combinations are needed to improve patient outcomes. Though more aggressive radiotherapy has reduced locoregional recurrences, median overall survival has not improved in more than 50 years.

Address: Medical Oncology Service, Hospital Universitario Central de Asturias, Avenida de Roma sn, 33011, Oviedo, Spain. [email protected].; CIBERDEM, Endocrinology and Nutrition Service, Hospital Universitario de Bellvitge, Barcelona, Spain.; Endocrinology and Nutrition Service, Hospital Universitario de Cruces, Vizcaya, Spain.; Medical Oncology Service, Hospital Universitario de la Vall d'Hebron, Barcelona, Spain.; Endocrinology and Nutrition Service, Hospital Universitario Virgen del Rocio, Sevilla, Spain.; Endocrinology and Nutrition Service, Hospital Universitario de la Vall d'Hebron, Barcelona, Spain.; Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.; Endocrinology and Nutrition Service, Hospital Universitario de Móstoles, Madrid, Spain.; Medical Oncology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain.; Endocrinology and Nutrition Service, Clínica Universidad de Navarra, Pamplona, Spain.

DOI: 10.1007/s12094-016-1506-0